# Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes

Study · id `cardio:ct-nct04974333` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04974333](<https://clinicaltrials.gov/study/NCT04974333>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04974333

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1512 participants.

## Technical summary

Registry record NCT04974333. Randomized; no masking; primary purpose treatment. Start 2021-10-04 (actual); primary completion 2023-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1512 participants (planned count; ClinicalTrials.gov record NCT04974333, source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)
- Started: 2021-10-04 (actual) (ClinicalTrials.gov record NCT04974333, source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)
- Primary completion: 2023-08-31 (anticipated) (ClinicalTrials.gov record NCT04974333, source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)
- Completion: 2024-02-28 (anticipated) (ClinicalTrials.gov record NCT04974333, source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT04974333, source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04974333-2022-03-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes
- Acronym: SANENT
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Mobile health application on phone
- Lead sponsor: General Health Council, Mexico
- Lead sponsor class: OTHER\_GOV
- Collaborator: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
- Collaborator class: OTHER\_GOV
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (`cardio:org-instituto-de-seguridad-y-servicios-sociales-de-los-4e32a0`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: bc3de567608775d7eabeed88b6147d6a423bc01f81d7b79c0fe6a29069c33129
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
